Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells

Cell Death and Differentiation

Volumn 7, Issue 7, 2000, Pages 637-644

  Wendling, U ^a   Walczak, H ^b   Dorr J ^a   Jaboci, C ^a   Weller, M ^c   Krammer, P H ^b   Zipp, F ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c University Hospital Charite ^*

Author keywords

Apoptosis; Multiple sclerosis; T lymphocytes; TRAIL

Indexed keywords

AUTOANTIGEN; CASPASE; DNA; RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

EID: 0033933918     PISSN: 13509047     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cdd.4400692     Document Type: Article

References (51)

1. Lenardo M, Ka-Ming Chan F, Hornung F, McFarland H, Siegel R, Wang J and Zheng L (1999) Mature Lymphocyte Apoptosis-Immune Regulation in a Dynamic and Unpredictable Antigenic Environment. Annu. Rev. Immunol. 17: 221-253
2. Pender MP (1999) Activation-induced apoptosis of autoreactive and alloreactive T lymphocytes in the target organ as a major mechanism of tolerance. Immunol. Cell Biol 77: 216-223
3. Alderson MR, Tough TW, Davis-Smith T, Braddy S, Falk B, Schooley KA, Goodwin RG, Smith CA, Ramsdell F and Lynch DH (1995) Fas ligand mediates activation-induced cell death in human T lymphocytes. J. Exp. Med. 181: 71-77
4. Dhein J, Walczak H, Bèumler C, Debatin KM and Krammer PH (1995) Autocrine T-cell suicide mediated by APO-1 (Fas/CD95). Nature 373: 438-441
5. Ju ST, Panka DJ, Cui H, Ettinger R, El-Khatib M, Sherr DH, Stanger BZ and Marshak-Rothstein A (1995) Fas (CD95)/FasL interactions required for programmed cell death after T cell-activation. Nature 373: 444-448
6. D'Souza SD, Bonetti B, Balasingam V, Cashman NR, Barker PA, Troutt AB, Raine CS and Antel JP (1996) Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184: 2361-2370
7. Dowling P, Shang G, Raval S, Menonna J, Cook S and Husar W (1996) Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain. J. Exp. Med. 184: 1513-1518
8. Zipp F, Krammer PH and Weller M (1999) Immune (dys)regulation in multiple sclerosis: role of the CD95/CD95 ligand system, Immunol. Today 20: 550-554
9. Schmied M, Breitschopf H, Gold R, Zischler H, Rothe G Wekerle H and Lassmann H (1993) Apoptosis of T lymphocytes in experimental autoimmune encephalomyelitis: Evidence for programmed cell death as a mechanism to control inflammation in the brain. Am. J. Pathology 143: 446-452
10. Critchfield JM, Racke MK, Zuniga-Pflucker JC, Cannella B, Raine CS, Goverman J and Lenardo MJ (1994) T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. Science 263: 1139-1143
11. Ishigami T, White CA and Pender MP (1998) Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs. Eur. J. Immunol. 28: 1626-1635
12. Zhou T, Song L, Yang P, Wang Z, Lui D and Jope RS (1999) Bisindolylmaleimide VIII faciltates Fas-mediated apoptosis and inhibits T cell-mediated autoimmune diseases. Nat. Med. 5: 42-48
13. Malipiero U, Frei K, Spanaus K-S, Agresti C, Lassmann H, Hahne M, Tschopp J, Eugster H-P and Fontana A (1997) Myelin oligodendrocyte glycoprotein-incluced encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas-and Fas ligand-deficient lpr and gld mice. Eur. J. Immunol. 27: 3151-3160
14. Waldner H, Sobel RA, Howard E and Kuchroo VK(1997) Fas-and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis. J. Immunol. 159: 3100-3103
15. Sabelko KA, Kelly KA, Nahm MH, Cross AH and Russell JH (1997) Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system. J. Immunol. 159: 3096-3099
16. Zipp F, Weller M, Calabresi PA, Frank JA, Bash CN, Dichgans J, McFarland H and Martin R (1998) Increased serum levels of soluble CD95 (APO1/Fas) in relapsing remitting multiple sclerosis. Ann. Neurol. 43: 116-120
17. Zipp F, Otzelberger K, Dichgans J, Martin R and Weller M (1998) Serum CD95 of multiple sclerosis patients protects from CD95-mediated apoptosis. J. Neuroimmunol. 86: 151-154
18. Ciusani E, Frigerio S, Gelati M, Corsini E, Dufour A, Nespolo A, La Mantia L, Milanese C, Massa G and Salmaggi A (1998) Soluble Fas (Apo-1) levels in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 82: 5-12
19. Zang YCQ, Kozovska MM, Hong J, Li S, Mann S, Killian JM, Rivera VM and Zhang JZ (1999) Impaired apoptotic deletion of myelin basic protein-reactive T cells in patients with multiple sclerosis. Eur. J. Immunol. 29: 1692-1700
20. Macchi B, Matteucci C, Nocentini U, Caltagirone C and Mastino A (1999) Impaired apoptosis in mitogen-stimulated lymphocytes of patients with multiple sclerosis. Neuroreport. 10: 399-402
21. Sabelko-Downes KA, Cross AH and Russell JH (1999) Dual role for Fas ligand in the initiation of and recovery from experimental allergic encephalomyelitis. J. Exp. Med. 189: 1195-1205
22. Klas C, Debatin KM, Jonker RR and Krammer PH (1993) Activation interferes with the APO-1 pathway in mature human T cells. Int. Immunol. 5: 625-630
23. Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM and Kramer PH (1997) Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol. 27: 1207-1212
24. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA and Goodwin RG (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682
25. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271: 12687-12690
26. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J and Dixit VM (1997) The receptor for the cytotoxic ligand TRAIL. Science 276: 111-113
27. Sheridan JP, Marsters S, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P and Ashkenazi A (1997) Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277: 818-821
28. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG and Rauch CT (1997) TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16: 5386-5397
29. Pan G, Ni J, Wei Y, Yu G, Gentz R and Dixit VM (1997) An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277: 815-818
30. Mongkolsapaya J, Cowper AE, Xu XN, Morris G, McMichael AJ, Bell J and Screaton GR (1998) Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocyte from the death ligand TRAIL. J. Immunol. 160: 3-6
31. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA and Goodwin RG (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7: 813-820
32. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J. Gurney A, Goddard AD, Godowski P and Ashkenzai A (1997) A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7: 1003-1006
33. Schneider P, Thome M, Burns K, Bodmer J-L, Hofman K, Kataoka T, Holler N and Tschopp J (1997) TRAIL receptors 1 (DR4) and 2 (DR5) Signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7: 831-836
34. Jeremias I, Herr I, Boehler T and Debatin KM (1998) TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28: 143-152
35. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P and Ashkenazi A (1996) Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA. Curr. Biol. 6: 750-752
36. Rieger J, Naumann U, Glaser T, Ashkenazi A and Weller M (1998) APO2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427: 124-128
37. Nagata S and Golstein P (1995) The Fas death factor. Science 267: 1449-1456
38. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middelton LA, Lin AY, Strober W, Lenardo MJ and Puck JM (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81: 935-946
39. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A and de Villartay JP (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268: 1347-1349
40. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL and Elkon KB (1996) Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335: 1643-1649
41. Le Deist F, Emile JF, Rieux-Laucat F, Benkerrou M, Roberts I, Brousse N and Fischer A (1996) Clinical, immunological, and pathological consequences of Fas-deficient conditions. Lancet 348: 719-723
42. Hohlfeld R, Meinl E, Weber F, Zipp F, Schmidt S, Sotgiu S, Goebels N, Voltz R, Spuler S, Iglesias A and Wekerle H (1995) The role of autoimmune T lymphocytes in the pathogenesis of multiple sclerosis. Neurology 45: S33-S38
43. Martin R, McFarland HF and McFarlin DE (1992) Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10: 153-187
44. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang C-P, DuBose RF, Goodwin RG and Smith CA (1997) Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186: 1165-1170
45. Zipp F, Martin R, Lichtenfels R, Roth W, Dichgans J, Krammer PH and Weller M (1997) Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. J. Immunol. 159: 2108-2115
46. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JACL and Lynch DH (1990) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5: 157-163
47. Martinez LM, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Pineiro A, Naval J and Anel A (1998) Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28: 2714-2725
48. Mariani SM and Krammer PH (1998) Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28: 973-982
49. Trauth BC, Klas C, Peters AMJ, Matzku S, Müller P, Falk W, Debatin KM and Krammer PH (1989) Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305
50. Riddell SR and Greenberg PD (1990) The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J. Immunol. Methods 128: 189-201
51. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F and Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139: 271-279